Skip to main content
Top

12-04-2024 | Barrett Esophagus | Original Article

Risk stratification for synchronous/metachronous recurrence after endoscopic submucosal dissection for Barrett’s esophageal adenocarcinoma using the length of Barrett’s esophagus

Authors: Yohei Ikenoyama, Ken Namikawa, Manabu Takamatsu, Yusuke Kumazawa, Yoshitaka Tokai, Shoichi Yoshimizu, Yusuke Horiuchi, Akiyoshi Ishiyama, Toshiyuki Yoshio, Toshiaki Hirasawa, Toru Ogura, Junko Fujisaki

Published in: Esophagus

Login to get access

Abstract

Background

In Japan, the standard management of Barrett’s esophageal adenocarcinoma after endoscopic submucosal dissection involves follow-up; however, multifocal synchronous/metachronous lesions are sometimes observed after endoscopic submucosal dissection. Risk stratification of multifocal cancer facilitates appropriate treatment, including eradication of Barrett’s esophagus in high-risk cases; however, no effective risk stratification methods have been established. Thus, we identified the risk factors for multifocal cancer and explored risk-stratified treatment strategies for residual Barrett’s esophagus.

Methods

We retrospectively reviewed the data of 97 consecutive patients with superficial Barrett’s esophageal adenocarcinomas who underwent curative resection with endoscopic submucosal dissection. Multifocal cancer was defined by the presence of synchronous/metachronous lesions during follow-up. We used Cox regression analysis to identify the risk factors for multifocal cancer and subsequently analyzed differences in cumulative incidences.

Results

The cumulative incidences of multifocal cancer at 1, 3, and 5 years were 4.4%, 8.6%, and 10.7%, respectively. Significant risk factors for multifocal cancer were increased circumferential and maximal lengths of Barrett’s esophagus. The cumulative incidences of multifocal cancer at 3 years were lower for patients with circumferential length < 4 cm and maximal length < 5 cm (2.9% and 1.2%, respectively) than for patients with circumferential length ≥ 4 cm and maximal length ≥ 5 cm (51.5% and 49.1%, respectively).

Conclusions

Risk stratification of multifocal cancer using length of Barrett’s esophagus was effective. Further multicenter prospective studies are needed to substantiate our findings.
Appendix
Available only for authorised users
Literature
2.
go back to reference Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 2009;24:729–35.CrossRefPubMed Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 2009;24:729–35.CrossRefPubMed
3.
go back to reference Thrift AP. Barrett’s esophagus and esophageal adenocarcinoma: how common are they really? Dig Dis Sci. 2018;63:1988–96.CrossRefPubMed Thrift AP. Barrett’s esophagus and esophageal adenocarcinoma: how common are they really? Dig Dis Sci. 2018;63:1988–96.CrossRefPubMed
4.
go back to reference Abe S, Ishihara R, Takahashi H, et al. Long-term outcomes of endoscopic resection and metachronous cancer after endoscopic resection for adenocarcinoma of the esophagogastric junction in Japan. Gastrointest Endosc. 2019;89:1120–8.CrossRefPubMed Abe S, Ishihara R, Takahashi H, et al. Long-term outcomes of endoscopic resection and metachronous cancer after endoscopic resection for adenocarcinoma of the esophagogastric junction in Japan. Gastrointest Endosc. 2019;89:1120–8.CrossRefPubMed
5.
go back to reference Katada C, Yokoyama T, Yano T, et al. Alcohol consumption and multiple dysplastic lesions increase risk of squamous cell carcinoma in the esophagus, head, and neck. Gastroenterology. 2016;151:860-9.e7.CrossRefPubMed Katada C, Yokoyama T, Yano T, et al. Alcohol consumption and multiple dysplastic lesions increase risk of squamous cell carcinoma in the esophagus, head, and neck. Gastroenterology. 2016;151:860-9.e7.CrossRefPubMed
6.
go back to reference Ishioka M, Yoshio T, Miyamoto Y, et al. Incidence of metachronous cancer after endoscopic submucosal dissection: a comparison between undifferentiated-type and differentiated-type early gastric cancer. Gastrointest Endosc. 2021;93:557-64.e1.CrossRefPubMed Ishioka M, Yoshio T, Miyamoto Y, et al. Incidence of metachronous cancer after endoscopic submucosal dissection: a comparison between undifferentiated-type and differentiated-type early gastric cancer. Gastrointest Endosc. 2021;93:557-64.e1.CrossRefPubMed
7.
go back to reference Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008;57:1200–6.CrossRefPubMed Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008;57:1200–6.CrossRefPubMed
8.
go back to reference Desai M, Saligram S, Gupta N, et al. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett’s esophagus-related neoplasia: a systematic review and pooled analysis. Gastrointest Endosc. 2017;85:482-95.e4.CrossRefPubMed Desai M, Saligram S, Gupta N, et al. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett’s esophagus-related neoplasia: a systematic review and pooled analysis. Gastrointest Endosc. 2017;85:482-95.e4.CrossRefPubMed
9.
go back to reference Abe K, Goda K, Kanamori A, et al. Whole circumferential endoscopic submucosal dissection of superficial adenocarcinoma in long-segment Barrett’s esophagus: a case report. World J Gastrointest Surg. 2021;13:1285–92.CrossRefPubMedPubMedCentral Abe K, Goda K, Kanamori A, et al. Whole circumferential endoscopic submucosal dissection of superficial adenocarcinoma in long-segment Barrett’s esophagus: a case report. World J Gastrointest Surg. 2021;13:1285–92.CrossRefPubMedPubMedCentral
10.
go back to reference Ishihara R, Oyama T, Abe S, et al. Risk of metastasis in adenocarcinoma of the esophagus: a multicenter retrospective study in a Japanese population. J Gastroenterol. 2017;52:800–8.CrossRefPubMed Ishihara R, Oyama T, Abe S, et al. Risk of metastasis in adenocarcinoma of the esophagus: a multicenter retrospective study in a Japanese population. J Gastroenterol. 2017;52:800–8.CrossRefPubMed
11.
go back to reference Moertel CG, Dockerty MB, Baggenstoss AH. Multiple primary malignant neoplasms. I. Introduction and presentation of data. Cancer. 1961;14:221–30.CrossRefPubMed Moertel CG, Dockerty MB, Baggenstoss AH. Multiple primary malignant neoplasms. I. Introduction and presentation of data. Cancer. 1961;14:221–30.CrossRefPubMed
12.
go back to reference Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part II and III. Esophagus. 2017;14:37–65.CrossRef Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part II and III. Esophagus. 2017;14:37–65.CrossRef
13.
go back to reference Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1–36.CrossRef Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1–36.CrossRef
14.
go back to reference Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRefPubMed Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRefPubMed
15.
go back to reference Fock KM, Talley N, Goh KL, et al. Asia–Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett’s oesophagus. Gut. 2016;65:1402–15.CrossRefPubMed Fock KM, Talley N, Goh KL, et al. Asia–Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett’s oesophagus. Gut. 2016;65:1402–15.CrossRefPubMed
16.
go back to reference Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1:87–97.CrossRef Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1:87–97.CrossRef
17.
go back to reference Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology. 1996;111:85–92.CrossRefPubMed Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology. 1996;111:85–92.CrossRefPubMed
18.
go back to reference Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology. 2006;131:1392–9.CrossRefPubMed Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology. 2006;131:1392–9.CrossRefPubMed
19.
go back to reference Lambert R. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003;58:S3-43.CrossRef Lambert R. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003;58:S3-43.CrossRef
20.
go back to reference Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed
21.
go back to reference Chandrasekar VT, Hamade N, Desai M, et al. Significantly lower annual rates of neoplastic progression in short- compared to long-segment non-dysplastic Barrett’s esophagus: a systematic review and meta-analysis. Endoscopy. 2019;51:665–72.CrossRefPubMed Chandrasekar VT, Hamade N, Desai M, et al. Significantly lower annual rates of neoplastic progression in short- compared to long-segment non-dysplastic Barrett’s esophagus: a systematic review and meta-analysis. Endoscopy. 2019;51:665–72.CrossRefPubMed
22.
go back to reference Shaheen NJ, Falk GW, Iyer PG, et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50 (quiz 51).CrossRefPubMed Shaheen NJ, Falk GW, Iyer PG, et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50 (quiz 51).CrossRefPubMed
23.
go back to reference Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy. 2017;49:191–8.CrossRefPubMed Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy. 2017;49:191–8.CrossRefPubMed
24.
go back to reference Abe S, Oda I, Suzuki H, et al. Long-term surveillance and treatment outcomes of metachronous gastric cancer occurring after curative endoscopic submucosal dissection. Endoscopy. 2015;47:1113–8.CrossRefPubMed Abe S, Oda I, Suzuki H, et al. Long-term surveillance and treatment outcomes of metachronous gastric cancer occurring after curative endoscopic submucosal dissection. Endoscopy. 2015;47:1113–8.CrossRefPubMed
25.
go back to reference Suzuki H, Ono H, Hirasawa T, et al. Long-term survival after endoscopic resection for gastric cancer: real-world evidence from a multicenter prospective cohort. Clin Gastroenterol Hepatol. 2023;21:307-18.e2.CrossRefPubMed Suzuki H, Ono H, Hirasawa T, et al. Long-term survival after endoscopic resection for gastric cancer: real-world evidence from a multicenter prospective cohort. Clin Gastroenterol Hepatol. 2023;21:307-18.e2.CrossRefPubMed
26.
go back to reference Ishihara R, Arima M, Iizuka T, et al. Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer. Dig Endosc. 2020;32:452–93.CrossRefPubMed Ishihara R, Arima M, Iizuka T, et al. Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer. Dig Endosc. 2020;32:452–93.CrossRefPubMed
27.
go back to reference Cotton CC, Wolf WA, Pasricha S, et al. Recurrent intestinal metaplasia after radiofrequency ablation for Barrett’s esophagus: endoscopic findings and anatomic location. Gastrointest Endosc. 2015;81:1362–9.CrossRefPubMedPubMedCentral Cotton CC, Wolf WA, Pasricha S, et al. Recurrent intestinal metaplasia after radiofrequency ablation for Barrett’s esophagus: endoscopic findings and anatomic location. Gastrointest Endosc. 2015;81:1362–9.CrossRefPubMedPubMedCentral
28.
go back to reference Titi M, Overhiser A, Ulusarac O, et al. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett’s esophagus. Gastroenterology. 2012;143:564-6.e1.CrossRefPubMed Titi M, Overhiser A, Ulusarac O, et al. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett’s esophagus. Gastroenterology. 2012;143:564-6.e1.CrossRefPubMed
29.
go back to reference Knabe M, Wetzka J, Welsch L, et al. Radiofrequency ablation versus hybrid argon plasma coagulation in Barrett’s esophagus: a prospective randomised trial. Surg Endosc. 2023;37:7803–11.CrossRefPubMedPubMedCentral Knabe M, Wetzka J, Welsch L, et al. Radiofrequency ablation versus hybrid argon plasma coagulation in Barrett’s esophagus: a prospective randomised trial. Surg Endosc. 2023;37:7803–11.CrossRefPubMedPubMedCentral
30.
go back to reference Tanaka I, Hirasawa D, Saito H, et al. Stepwise endoscopic submucosal dissection for circumferential Barrett’s esophageal dysplasia and carcinoma: a case series. Endosc Int Open. 2022;10:E215–21.CrossRefPubMedPubMedCentral Tanaka I, Hirasawa D, Saito H, et al. Stepwise endoscopic submucosal dissection for circumferential Barrett’s esophageal dysplasia and carcinoma: a case series. Endosc Int Open. 2022;10:E215–21.CrossRefPubMedPubMedCentral
Metadata
Title
Risk stratification for synchronous/metachronous recurrence after endoscopic submucosal dissection for Barrett’s esophageal adenocarcinoma using the length of Barrett’s esophagus
Authors
Yohei Ikenoyama
Ken Namikawa
Manabu Takamatsu
Yusuke Kumazawa
Yoshitaka Tokai
Shoichi Yoshimizu
Yusuke Horiuchi
Akiyoshi Ishiyama
Toshiyuki Yoshio
Toshiaki Hirasawa
Toru Ogura
Junko Fujisaki
Publication date
12-04-2024
Publisher
Springer Nature Singapore
Published in
Esophagus
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-024-01058-8
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine